^
Association details:
| Biomarker: | CD73 elevation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + oleclumab (MEDI9447) (CD73 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Published date:
11/30/2023
Excerpt:
...we investigated the prognostic value of the soluble form of CD73 (sCD73) in patients with advanced triple negative breast cancer (TNBC) treated with first-line durvalumab and chemotherapy, with or without anti-CD73 antibody oleclumab in the randomized, phase II SYNERGY trial (NCT03616886)....Median overall survival (OS) was significantly shorter in patients with high baseline sCD73 levels compared to those with low sCD73 (18.8 vs. 26.4 months; log-rank, p=0.03).
Secondary therapy:
Chemotherapy
Trial ID:
